Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Manish Kohli, MD
Advertisement
Articles by Manish Kohli, MD
Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.
Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.
Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.
Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).
Advertisement
Latest Updated Articles
Dr. Kohli Discusses Ongoing Correlative Science in Prostate CancerSeptember 10th 2019
Dr. Kohli on the Challenges of Molecular Classification in Prostate CancerSeptember 25th 2019
Dr. Kohli on Drugs That Have Been Evaluated in mCRPCJanuary 24th 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5